249 results on '"Riely G"'
Search Results
2. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Patients with Pleural Metastases from Thymic Malignancies
3. Treatment of Thymic Oligometastastic or Oligoprogressive Lesions with Hypofractionated Radiation Therapy or Stereotactic Body Radiation Therapy
4. MA06.13 Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study
5. OA18.06 Characteristics and Outcomes of Patients with SMARCA4-Deficient Undifferentiated Thoracic Tumors
6. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers†
7. FP09.01 Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy
8. OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
9. P39.01 Long-Term Outcomes and Characteristics of Unresectable Locally Advanced Thymic Malignancies
10. FP09.02 Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort
11. Colloid adenocarcinoma of the lung
12. OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
13. P90.03 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
14. P09.58 Replication of Overall Survival in Chemotherapy Arms of 1L NSCLC Trials using Real-World Data External Controls
15. P09.60 Using Patient-Level Data from Electronic Health Records to Replicate PFS Outcomes for Four 1L NSCLC Trials
16. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
17. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
18. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
19. Circulating Tumor DNA as a Biomarker in Oligometastatic Non-small Cell Lung Cancer
20. A07 The Genomic Landscape of SMARCA4 Alterations and Association with Patient Outcomes in Lung Cancer
21. P1.01-127 Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions
22. P1.14-12 A Novel Activating MAP2K1 In-Frame Deletion Mediates Acquired Resistance to ROS1 TKIs in a Patient with ROS1 Fusion-Positive NSCLC
23. ES06.03 Future Strategies in Second Line Treatment
24. P1.04-39 Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers
25. P1.01-25 Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles
26. P1.14-06 Tissue-Based Molecular and Histologic Landscape of Acquired Resistance to Osimertinib in Patients with EGFR-Mutant Lung Cancers
27. P1.14-50 A Phase 2 Trial of Cabozantinib in ROS1-Rearranged Lung Adenocarcinoma
28. P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
29. OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6
30. P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789
31. OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
32. MA19.09 Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB
33. P1.01-75 Utility of cfDNA Testing for Acquired Resistance: The Memorial Sloan Kettering Experience with Plasma EGFR T790M Clinical Testing
34. P1.01-74 MET Exon 14-Altered Lung Cancers: Central Nervous System (CNS) Metastases and Patterns of CNS Progression on MET Inhibition
35. OA 12.06 Plasma Genomic Profiling and Outcomes of Patients with MET Exon 14-Altered NSCLCs Treated with Crizotinib on PROFILE 1001
36. P1.01-012 Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis
37. OA 03.03 Phase II Trial of Cetuximab and Chemotherapy Followed by Surgical Resection for Locally Advanced Thymoma
38. OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers
39. OA 10.03 Liquid Biopsy in the Lung Cancer Clinic: A Prospective Study of Plasma DNA next Generation Sequencing to Guide Matched Therapy
40. Crizotinib in ROS1 -rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
41. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) : An Update of ASCEND-1: Metastatic Non-Small Cell Lung Cancer
42. Ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK plus) non small cell lung cancer (NSCLO) and brain metastases (BM) in the ascend-1 trial
43. Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology
44. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1
45. BM-32 * CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL
46. Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?
47. alpha2-macroglobulin modulates the immunoregulatory function of the lipocalin placental protein 14
48. Abstract B31: Single-agent pemetrexed in patients with ALK-positive NSCLC: A retrospective analysis of investigator-reported outcomes
49. Nomogramme prédictif des mutations activatrices de l’EGFR dans les adénocarcinomes pulmonaires
50. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: Executive Summary
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.